The ATM gene has been described as a frequent CHIP clone in clinical cancer predisposition testing, along with CHEK2 and TP53. 10 We speculate that CHIP interference in cfDNA testing could be affecting results of PARPi clinical studies of patients with metastatic prostate cancer. This evidence concerns the gene STUB1 and metastatic prostate carcinoma.